GlassScriptPhysician profile
Rommel De Vera
NPI 1407383904
$5,289.89
in general payments reported to CMS, 2019-2025
27 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $430 · 2021: $1,550 · 2022: $499 · 2023: $706 · 2024: $980 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.83 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,427.90 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,030.31 | 2020-2025 | Farxiga, Airsupra, Flumist Quadrivalent |
| Novo Nordisk INC | $485.45 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $377.12 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $342.06 | 2022 | |
| Pfizer INC. | $267.37 | 2019-2025 | |
| Lilly USA, LLC | $206.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $203.89 | 2023-2025 | Qulipta |
| Astellas Pharma US INC | $195.55 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $164.63 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.24 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $87.87 | 2025 | Arexvy, Shingrix, Nucala |
| Exact Sciences Corporation | $50.44 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.45 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $34.56 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.60 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $32.13 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.42 | 2021-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $25.04 | 2023 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $22.95 | 2023 | Freestyle Libre 2 |
| Boston Scientific Corporation | $16.80 | 2024 | |
| Insulet Corporation | $16.00 | 2020 | |
| Curonix LLC | $15.86 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Takeda Pharmaceuticals U.S.A., INC. | $14.90 | 2022 | |
| Currax Pharmaceuticals LLC | $14.43 | 2022 | |
| Coala Life INC | $14.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.20 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rommel De Vera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.